英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
puberulent查看　puberulent　在百度字典中的解释百度英翻中〔查看〕
puberulent查看　puberulent　在Google字典中的解释Google英翻中〔查看〕
puberulent查看　puberulent　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • 英派药业 | IMPACT Therapeutics
    Make an IMPACT on Cancer Treatment Founded in 2009, Impact Therapeutics is a commercial-stage biotechnology company focused on advancing synthetic lethality (SL)-based precision anti-cancer therapies globally, delivering innovative treatments to address the unmet medical needs of cancer patients
  • 英派药业 | IMPACT Therapeutics
    英派药业官方网站 Make an IMPACT on Cancer Treatment 英派药业成立于2009年，是一家处于商业化阶段的生物技术公司，致力于在全球范围内推进基于合成致死机制的精准抗癌疗法，打造创新疗法，以满足癌症患者未被满足的医疗需求。公司通过自主研发建立了最全面、最先进的合成致死产品组合之一，也是
  • 英派药业 | IMPACT Therapeutics
    英派药业官方网站 Company Overview Leadership Team Board of Directors Our History
  • 英派药业 | IMPACT Therapeutics
    英派药业官方网站 地址：上海市浦东新区海阳西路399号前滩时代广场27层 产品服务热线：400-008-4297 不良反应投诉邮箱：MAHPV@impacttherapeutics com 邮箱: info@impacttherapeutics com
  • 英派药业 | IMPACT Therapeutics
    地址：上海市浦东新区海阳西路399号前滩时代广场27层 产品服务热线：400-008-4297 不良反应投诉邮箱：MAHPV@impacttherapeutics com 邮箱: info@impacttherapeutics com
  • 英派药业 | IMPACT Therapeutics
    英派药业官方网站
  • 英派药业 | IMPACT Therapeutics
    Address: 27F, Qiantan Times Square, No 399 Haiyang West Road, Pudong New Area, Shanghai Hotline: 400-008-4297 AE Reporting: MAHPV@impacttherapeutics com email: info@impacttherapeutics com
  • IMPACT Announces Results of Senaparib for PSOC at ESMO2025
    About IMPACT Therapeutics Founded in 2009, IMPACT Therapeutics is a commercial-stage, innovation-driven biotechnology company focused on advancing synthetic lethality (SL)-based precision anti-cancer therapies globally to redefine standard of care
  • IMPACT Therapeutics Announces Phase 3 Clinical Study of Senaparib for . . .
    IMPACT Therapeutics, in collaboration with our partner Junshi Biosciences, will communicate with regulatory authorities regarding a new drug application for Senaparib in the near future Dr Sui Xiong CAI, Chief Executive Officer of IMPACT Therapeutics, commented on the positive results of the FLAMES study
  • IMPACT Announces Completion of RMB 250 million Sr. D++ Financing
    SHANGHAI, November 15th, 2024 - IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, announced the successful completion of its Series D++ financing of RMB 250 million





中文字典-英文字典  2005-2009